DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds.
"Astellas has made significant progress over the last year toward becoming a global category leader in oncology with the integration of OSI oncology and further development of the pipeline. Mark's breadth of product experience, along with his proven leadership capabilities, will be instrumental in Astellas' future success in oncology," said Shea. "We are excited to add Mark to our management team."
The majority of Mark's 20-plus year career has been committed to oncology therapies, where he has had sales and marketing responsibilities in a variety of capacities (domestic and global) at Abbott, Pharmacia, Bristol-Myers Squibb and Zeneca. Most recently, Mark has served as senior vice president and chief commercial officer of Micromet Inc. where he was involved in investor and public relations, clinical strategy, business development, and commercial launch planning.
Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the U.S., Astellas markets products in the areas of Anti-Infectives, Cardiology, Dermatology, Neuroscience, Transplant, Oncology and Urology. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.us or follow us on Twitter at www.Twitter.com/AstellasUS.
SOURCE Astellas Pharma US, Inc.